Association between adjuvant EGFR-TKI therapy and survival outcomes in completely resected stage I invasive lung adenocarcinoma (≤3 cm) with sensitizing EGFR mutations and pathological high-risk features
- DOI
- 10.21037/tlcr-2026-0951
- Published
- 2026-10
- Container
- Translational Lung Cancer Research
- Publisher
- AME Publishing Company
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.21037/tlcr-2026-0951,
title = {Association between adjuvant EGFR-TKI therapy and survival outcomes in completely resected stage I invasive lung adenocarcinoma (≤3 cm) with sensitizing EGFR mutations and pathological high-risk features},
author = {Jie Cao and Zhaokang Huang and Fang Qiu and Nan Chen and Zhiyu Peng and Zetao Liu and Xizhou Liao and Xiaorong Zong and Peidi Li and Chenglin Guo and Jiandong Mei and Lunxu Liu},
year = {2026},
journal = {Translational Lung Cancer Research},
doi = {10.21037/tlcr-2026-0951},
url = {https://doi.org/10.21037/tlcr-2026-0951}
}RIS
TY - JOUR TI - Association between adjuvant EGFR-TKI therapy and survival outcomes in completely resected stage I invasive lung adenocarcinoma (≤3 cm) with sensitizing EGFR mutations and pathological high-risk features AU - Jie Cao AU - Zhaokang Huang AU - Fang Qiu AU - Nan Chen AU - Zhiyu Peng AU - Zetao Liu AU - Xizhou Liao AU - Xiaorong Zong AU - Peidi Li AU - Chenglin Guo AU - Jiandong Mei AU - Lunxu Liu PY - 2026 JO - Translational Lung Cancer Research DO - 10.21037/tlcr-2026-0951 UR - https://doi.org/10.21037/tlcr-2026-0951 ER -
APA
Cao, J., Huang, Z., Qiu, F., Chen, N., Peng, Z., Liu, Z., Liao, X., Zong, X., Li, P., Guo, C., Mei, J., & Liu, L. (2026). Association between adjuvant EGFR-TKI therapy and survival outcomes in completely resected stage I invasive lung adenocarcinoma (≤3 cm) with sensitizing EGFR mutations and pathological high-risk features. Translational Lung Cancer Research. https://doi.org/10.21037/tlcr-2026-0951
Source records
- crossref · retrieved 2026-11-09T17:34:39.451Z